Assenagon Asset Management S.A. Sells 132,516 Shares of Harvard Bioscience, Inc. (NASDAQ:HBIO)

Assenagon Asset Management S.A. decreased its holdings in Harvard Bioscience, Inc. (NASDAQ:HBIO) by 65.5% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 69,799 shares of the medical instruments supplier’s stock after selling 132,516 shares during the period. Assenagon Asset Management S.A. owned about 0.16% of Harvard Bioscience worth $147,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. GSA Capital Partners LLP acquired a new position in shares of Harvard Bioscience in the third quarter valued at about $30,000. SG Americas Securities LLC acquired a new position in shares of Harvard Bioscience during the 3rd quarter worth approximately $36,000. Avior Wealth Management LLC grew its position in shares of Harvard Bioscience by 1,118.1% during the 3rd quarter. Avior Wealth Management LLC now owns 14,569 shares of the medical instruments supplier’s stock worth $39,000 after purchasing an additional 13,373 shares in the last quarter. Cubist Systematic Strategies LLC bought a new position in shares of Harvard Bioscience during the second quarter worth approximately $40,000. Finally, Landscape Capital Management L.L.C. acquired a new stake in shares of Harvard Bioscience in the third quarter valued at approximately $50,000. 80.87% of the stock is owned by institutional investors and hedge funds.

Harvard Bioscience Trading Down 5.4 %

HBIO opened at $1.74 on Friday. The stock has a market capitalization of $75.90 million, a price-to-earnings ratio of -5.27 and a beta of 1.27. The company has a quick ratio of 0.91, a current ratio of 2.06 and a debt-to-equity ratio of 0.52. Harvard Bioscience, Inc. has a twelve month low of $1.73 and a twelve month high of $4.93. The company has a 50-day simple moving average of $2.11 and a 200 day simple moving average of $2.53.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.